Hikma Pharmaceuticals Plc Hikma Delivers Insights at World Economic Forum
January 27 2015 - 9:14AM
RNS Non-Regulatory
TIDMHIK
Hikma Pharmaceuticals Plc
27 January 2015
Publication date: 27 January 2015
Hikma Pharmaceuticals Delivers Insights on MENA Growth Markets'
at 45(th) World Economic Forum
Covering impact of oil prices, political risk and demographic
shifts
Amman, January 2015 - Hikma Pharmaceuticals PLC ("Hikma") (LSE:
HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing
multinational pharmaceutical group, joined the 45(th) World
Economic Forum (WEF) Annual Meeting in Davos-Klosters, Switzerland,
held on January 21 - 24, 2015, to provide insights on the impact of
recent societal, political and economic developments on growth
markets in the Arab World. Serving as a WEF Regional Associate for
the second consecutive year, Hikma was one of 2,540 business,
government, academic and civil society leaders to convene this year
to explore solutions for pressing international, regional and
industry issues within 'The New Global Context' - the Forum's theme
- as brought on by breakthrough technologies, demographic shifts
and political transformations.
Representing Hikma, Mazen Darwazeh, Vice Chairman, President and
CEO of MENA and Emerging Markets, participated as a discussion
leader in the 'Arab World Growth Markets' session alongside
Jordan's Minister of Finance, Umayya Toukan; the Palestinian
National Authority's Deputy Prime Minister and Minister of Economy,
Mohammad Mustafa; and Dana Gas PJSC's CEO, Patrick Allman-Ward.
During the session, Darwazah elaborated on the economic
consequences of falling oil prices; the potential of cross-sector
and public-private integration; as well as the need for greater
investment in, and Hikma's contribution to, talent and education
development.
"Public-private and international cooperation is key to ensuring
the sustainable growth of worldwide economies in the face of
significant oil price shocks, geopolitical tensions and the
persistent gap in scientific, technical and human skills," said
Darwazeh. "As a rapidly-growing multinational group with markets in
more than 50 countries, Hikma is committed to helping communities
boost their resilience and adaptability to societal, political and
commercial changes, a vision that is reflected in our partnership
with the WEF."
-End-
About Hikma Pharmaceuticals
Hikma Pharmaceuticals is a fast growing multinational group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based principally in the
Middle East and North Africa (MENA) region, where it is a market
leader, the United States and Europe. In December 2013, Hikma had
7,067 employees worldwide.
For further news and information, please visit www.hikma.com or
contact:
Hana Darwazeh Ramadan
Email: media@hikma.com
Tel: +962 6 580 2900
This press release has been distributed by Bidaya Corporate
Communications on behalf of Hikma Pharmaceuticals.
For more information or assistance, please contact us at:
Tel: +962 6 585 4002/6
Fax: +962 6 585 3001
P.O. Box: 930391, Amman 11193, Jordan
Email: media@bidayacorp.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAMMGZMDNMGKZM
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024